We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
- Authors
Allavena, Clotilde; Flandre, Philippe; Pugliese, Pascal; Valantin, Marc-Antoine; Poizot-Martin, Isabelle; Cabié, André; Melliez, Hugues; Cuzin, Lise; Duvivier, Claudine; Dellamonica, Pierre; Raffi, François; Dat'aids Group
- Abstract
In highly antiretroviral-experienced patients with a multidrug-resistant human immunodeficiency virus (HIV) infection, recommended regimens should preferentially contain 3 active components, including a ritonavir-boosted protease inhibitor (PI/r). Tipranavir/r (TPV/r), a non-peptidic PI, has been specifically developed for patients resistant to the usual antiretroviral classes including PIs. This paper discusses the role of TPV/r in patients experiencing multiple PI resistance.
- Publication
Scandinavian journal of infectious diseases, 2012, Vol 44, Issue 1, p37
- ISSN
1651-1980
- Publication type
Journal Article
- DOI
10.3109/00365548.2011.598870